Filing Flows › Aktis Oncology (AKTS) › Q1 2026 › vs Q1 2025
Aktis Oncology (AKTS) Q1 2026 vs Q1 2025 (year over year)
Aktis Oncology's revenue rose $1.8M (+123%) from $1.4M in Q1 2025 to $3.2M in Q1 2026.
Aktis Oncology, Q1 2026: revenue $3.2M (+123% year over year), operating margin -703.6%, net loss $18.3M, operating cash flow −$24.2M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.2M | $1.4M | $1.8M | +123% |
| Other income, net | $4.4M | $3.2M | $1.2M | +39% |
| Net loss | $18.3M | $15.0M | $3.3M | +22% |
| Costs & expenses | $25.9M | $19.6M | $6.3M | +32% |
| Operating costs | $25.9M | $19.6M | $6.3M | +32% |
| Research & development | $20.0M | $15.9M | $4.2M | +26% |
| General & admin | $5.9M | $3.7M | $2.2M | +58% |
| Operating cash sources | $27.9M | $19.2M | $8.7M | +45% |
| Depreciation & amortization | $652K | $484K | $168K | +35% |
| Share-based compensation | $3.0M | $1.2M | $1.8M | +145% |
| Cash used in operations | $24.2M | $17.5M | $6.8M | +39% |
| Net loss absorbed | $18.3M | $15.0M | $3.3M | +22% |
| Working capital & other | $9.6M | $4.2M | $5.4M | +127% |
Questions
How much did Aktis Oncology's revenue grow year over year in Q1 2026?
Aktis Oncology's revenue rose $1.8M (+123%) from $1.4M in Q1 2025 to $3.2M in Q1 2026.